Bone marrow derived stem cells in regenerative medicine as advanced therapy medicinal products

American Journal of Translational Research

Volumn 2, Issue 3, 2010, Pages 285-295

  Astori, Giuseppe ^a   Soncin, Sabrina ^a   Cicero, Viviana Lo ^a   Siclari, Francesco ^a   Sürder, Daniel ^a   Turchetto, Lucia ^a   Soldati, Gianni ^a   Moccetti, Tiziano ^a  

^a DIVISION OF CARDIOLOGY   (Switzerland)

Author keywords

Acute myocardial infarction; Advanced therapy medicinal products; Cell factory; Good manufacturing practice; Peripheral vascular disease; Stem cells

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN;

ACUTE HEART INFARCTION; ANGIOGENESIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BRAIN ISCHEMIA; CARCINOGENICITY; CARDIOMYOPATHY; CELL ISOLATION; CELL THERAPY; CLINICAL TRIAL; COLONY FORMING UNIT; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; ENDOTHELIUM CELL; GOOD MANUFACTURING PRACTICE; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEG ISCHEMIA; LIMB AMPUTATION; MEDICAL LITERATURE; MONONUCLEAR CELL; MUSCLE REGENERATION; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; REGENERATIVE MEDICINE; REGULATORY MECHANISM; REVIEW;

EID: 77954678396     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968, 2:1366-1369.
2. Kuci S, Kuci Z, Latifi-Pupovci H, Niethammer D, Handgretinger R, Schumm M, Bruchelt G, Bader P, Klingebiel T: Adult stem cells as an alternative source of multipotential (pluripotential) cells in regenerative medicine. Curr Stem Cell Res Ther 2009, 4:107-117.
3. Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968, 97:77-89.
4. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH: Viable offspring derived from fetal and adult mammalian cells. Nature 1997, 385:810-813.
5. Noort WA, Kruisselbrink AB, in't Anker PS, Kruger M, van Bezooijen RL, de Paus RA, Heemskerk MH, Lowik CW, Falkenburg JH, Willemze R, Fibbe WE: Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol 2002, 30:870-878.
6. Sutherland DR, Keating A: The CD34 antigen: structure, biology, and potential clinical applications. J Hematother 1992, 1:115-129.
7. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997, 90:5013-5021.
8. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
9. Colter DC, Class R, DiGirolamo CM, Prockop DJ: Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci U S A 2000, 97:3213-3218.
10. Lee JH, Kosinski PA, Kemp DM: Contribution of human bone marrow stem cells to individual skeletal myotubes followed by myogenic gene activation. Exp Cell Res 2005, 307:174-182.
11. Urbich C, Dimmeler S: Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004, 95:343-353.
12. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
13. Valgimigli M, Rigolin GM, Fucili A, Porta MD, Soukhomovskaia O, Malagutti P, Bugli AM, Bragotti LZ, Francolini G, Mauro E, et al: CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 2004, 110:1209-1212.
14. Kinnaird T, Stabile E, Burnett MS, Epstein SE: Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res 2004, 95:354-363.
15. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003, 348:593-600.
16. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999, 85:221-228.
17. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, Deliliers GL: Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br J Haematol 2001, 115:186-194.
18. Hirschi KK, Ingram DA, Yoder MC: Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008, 28:1584-1595.
19. Mund JA, Ingram DA, Yoder MC, Case J: Endothelial progenitor cells and cardiovascular cellbased therapies. Cytotherapy 2009, 11:103-113.
20. Gnecchi M, Zhang Z, Ni A, Dzau VJ: Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008, 103:1204-1219.
21. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ: Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005, 11:367-368.
22. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ: Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cellmediated cardiac protection and functional improvement. Faseb J 2006, 20:661-669.
23. Roger VL, Weston SA, Redfield MM, HellermannHoman JP, Killian J, Yawn BP, Jacobsen SJ: Trends in heart failure incidence and survival in a community-based population. Jama 2004, 292:344-350.
24. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, et al: Bone marrow cells regenerate infarcted myocardium. Nature 2001, 410:701-705.
25. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK, Goodell MA: Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001, 107:1395-1402.
26. Dawn B, Bolli R: Adult bone marrow-derived cells: regenerative potential, plasticity, and tissue commitment. Basic Res Cardiol 2005, 100:494-503.
27. Rota M, Kajstura J, Hosoda T, Bearzi C, Vitale S, Esposito G, Iaffaldano G, Padin-Iruegas ME, Gonzalez A, Rizzi R, et al: Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci U S A 2007, 104:17783-17788.
28. Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, David A, Liebold A, Nienaber C, Zurakowski D, et al: Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg 2007, 133:717-725.
29. Cannon RO, 3rd, Dunbar CE: BM-derived cell therapies for cardiovascular disease. Cytotherapy 2007, 9:305-315.
30. Yoon YS, Lee N, Scadova H: Myocardial regeneration with bone-marrow-derived stem cells. Biol Cell 2005, 97:253-263.
31. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B: Adult bone marrow-derived cells for cardiac repair: a systematic review and metaanalysis. Arch Intern Med 2007, 167:989-997.
32. Sürder D SJ, Moccetti T, Astori G, Rufibach K, Plein S, Lo Cicero V, Soncin S, Windecker S, Moschovitis A, Erne P, Jamshidi P, Auf der Maur C, Manka R, Soldati G, Landmesser U, Lüscher TF and Corti R.: Cell-based therapy for myocardial repair in patients with acute myocardial infarction: Rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISSAMI). AHJ 2010, accepted for pubblication.
33. Guidelines for percutaneous transluminal angioplasty. Standards of Practice Committee of the Society of Cardiovascular and Interventional Radiology. Radiology 1990, 177:619-626.
34. Valentine RJ, Myers SI, Inman MH, Roberts JR, Clagett GP: Late outcome of amputees with premature atherosclerosis. Surgery 1996, 119:487-493.
35. Schainfeld RM, Isner JM: Critical limb ischemia: nothing to give at the office? Ann Intern Med 1999, 130:442-444.
36. Hiatt WR: Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001, 344:1608-1621.
37. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001, 7:430-436.
38. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T: Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 2000, 97:3422-3427.
39. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner JM, Asahara T: Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001, 103:634-637.
40. Shintani S, Murohara T, Ikeda H, Ueno T, Sasaki K, Duan J, Imaizumi T: Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 2001, 103:897-903.
41. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R, Masaki H, Mori Y, Iba O, Tateishi E, et al: Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001, 104:1046-1052.
42. Dimmeler S, Zeiher AM, Schneider MD: Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest 2005, 115:572-583.
43. Lenk K, Adams V, Lurz P, Erbs S, Linke A, Gielen S, Schmidt A, Scheinert D, Biamino G, Emmrich F, et al: Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. Eur Heart J 2005, 26:1903-1909.
44. Kawamura A, Horie T, Tsuda I, Ikeda A, Egawa H, Imamura E, Iida J, Sakata H, Tamaki T, Kukita K, et al: Prevention of limb amputation in patients with limbs ulcers by autologous peripheral blood mononuclear cell implantation. Ther Apher Dial 2005, 9:59-63.
45. Huang PP, Li SZ, Han MZ, Xiao ZJ, Yang RC, Qiu LG, Han ZC: Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. Thromb Haemost 2004, 91:606-609.
46. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC: Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005, 28:2155-2160.
47. Van Tongeren RB, Hamming JF, Fibbe WE, Van Weel V, Frerichs SJ, Stiggelbout AM, Van Bockel JH, Lindeman JH: Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. J Cardiovasc Surg (Torino) 2008, 49:51-58.
48. Cobellis G, Silvestroni A, Lillo S, Sica G, Botti C, Maione C, Schiavone V, Rocco S, Brando G, Sica V: Long-term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplant 2008, 42:667-672.
49. Bittner RE, Schofer C, Weipoltshammer K, Ivanova S, Streubel B, Hauser E, Freilinger M, Hoger H, Elbe-Burger A, Wachtler F: Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat Embryol (Berl) 1999, 199:391-396.
50. Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, Boggs SS, Greenberger JS, Goff JP: Bone marrow as a potential source of hepatic oval cells. Science 1999, 284:1168-1170.
51. Theise ND, Nimmakayalu M, Gardner R, Illei PB, Morgan G, Teperman L, Henegariu O, Krause DS: Liver from bone marrow in humans. Hepatology 2000, 32:11-16.
52. Ianus A, Holz GG, Theise ND, Hussain MA: In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest 2003, 111:843-850.
53. Hess D, Li L, Martin M, Sakano S, Hill D, Strutt B, Thyssen S, Gray DA, Bhatia M: Bone marrowderived stem cells initiate pancreatic regeneration. Nat Biotechnol 2003, 21:763-770.
54. Grove JE, Bruscia E, Krause DS: Plasticity of bone marrow-derived stem cells. Stem Cells 2004, 22:487-500.
55. Dietz AB, Padley DJ, Gastineau DA: Infrastructure development for human cell therapy translation. Clin Pharmacol Ther 2007, 82:320-324.
56. EudraLex. The Rules Governing Medicinal Products in the European Union Volume 4. EU Guidelines toGood Manufacturing Practice. Medicinal Products for Human and Veterinary Use. Annex 1. Manufacture of Sterile Medicinal Products (corrected version). 2008.
57. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline validation of analytical procedures: text and methodology Q2(R1). 1994.
58. Directive 2004/23/EC of the European Parliament and of the Council on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. 2004.
59. Food and Drug Administration. Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 2007.
60. Griesel C, Heuft HG, Herrmann D, Franke A, Ladas D, Stiehler N, Stucki A, Braun M, Wollert KC, Meyer GP, et al: Good manufacturing practicecompliant validation and preparation of BM cells for the therapy of acute myocardial infarction. Cytotherapy 2007, 9:35-43.
61. Research FaDACfBEa: Guidance for FDA Reviewers and Sponsors: content and review of chemistry, manufacturing, and control (CMC) information for human somatic cell therapy investigational new drug applications (IND). (Services UdoHaH ed.; 2008.
62. Soncin S, Lo Cicero V, Astori G, Soldati G, Gola M, Surder D, Moccetti T: A practical approach for the validation of sterility, endotoxin and potency testing of bone marrow mononucleated cells used in cardiac regeneration in compliance with good manufacturing practice. J Transl Med 2009, 7:78.
63. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S: Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007, 28:766-772.
64. Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A, Walter DH, Martin H, Zeiher AM, Dimmeler S: Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004, 109:1615-1622.
65. Britten MB, Abolmaali ND, Assmus B, Lehmann R, Honold J, Schmitt J, Vogl TJ, Martin H, Schachinger V, Dimmeler S, Zeiher AM: Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 2003, 108:2212-2218.
66. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, et al: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004, 364:141-148.
67. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, et al: Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006, 113:1287-1294.
68. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, et al: Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006, 355:1210-1221.
69. Huikuri HV, Kervinen K, Niemela M, Ylitalo K, Saily M, Koistinen P, Savolainen ER, Ukkonen H, Pietila M, Airaksinen JK, et al: Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J 2008, 29:2723-2732.
70. Nijveldt.: Intracoronary Infusion of Mononuclear Cells After PrimaryPercutaneous Coronary Intervention: The HEBE Trial. Circulation 2008, 118 (2008 Late-Breaking Clinical Trial Abstracts): 2309-2317.
71. Tendera M, Wojakowski W, Ruzyllo W, Chojnowska L, Kepka C, Tracz W, Musialek P, Piwowarska W, Nessler J, Buszman P, et al: Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009, 30:1313-1321.
72. Lunde K, Solheim S, Aakhus S, Arnesen H, Moum T, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Forfang K: Exercise capacity and quality of life after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: results from the Autologous Stem cell Transplantation in Acute Myocardial Infarction (ASTAMI) randomized controlled trial. Am Heart J 2007, 154:710 e711-718.